Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cassava Sciences, Inc.
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
August 08, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
August 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET
August 01, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Expansion of Open-Label Extension Trials
July 30, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
July 17, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
MDXG
SAVA
SRPT
Cassava Sciences Issues Statement on Former Science Advisor
June 28, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
May 10, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
May 08, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
May 01, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Redemption Date Announced for Warrants
April 15, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
March 25, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
March 04, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
February 07, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
January 05, 2024
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
December 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Appoints Three New Members to its Board of Directors
December 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
November 07, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
November 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
October 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 02, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
September 06, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 03, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 05, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
New Publication Highlights Basic Science Supporting Simufilam
June 12, 2023
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Tickers
SAVA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.